Prospective Cohort of Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer FRESH-PEF60092-en François GHIRINGHELLI Prospective Cohort of Patients Receiving Neoadjuvant Chemotherapy for Breast Cancer BREAST CANCER CHEMOTHERAPY FRESH-PEF60092-en 60092 FRESH-PEF60092 François GHIRINGHELLI CENTRE HOSPITALIER UNIVERSITAIRE DE DIJON Epidemiology France Portal (PEF) CENTR GEORGES FRANCOIS LECLERC null François;GHIRINGHELLI state local recurrence metastatic histological data imaging Health episodes death treatment classification surgery Oncology Malignant neoplasms of breast Healthcare system determinants: Use of care Healthcare system determinants General objective: To evaluate the medical, clinical, biological and therapeutic characteristics of breast cancer patients receiving neoadjuvant chemotherapy Secondary objectives: - To evaluate the long-term impact of therapeutic schemas on recurrence-free overall survival; - To validate the current prognostic scores from a U.S. population on an independent French cohort; - To identify prognostic variables and select those relevant to the establishment and evaluation of a new score from our database to reflect new biological data (Chevallier and Sataloff scores and molecular classification); - To compare the prognostic qualities of the new score to the U.S. score; - To conduct an external validation of these scores (through collaboration with the Institut Gustave Roussy team in Villejuif and the Institute Bergonie team in Bordeaux); - To isolate genetic (constitutional), genomic (tumour) or immunohistological factors with predictive power for treatment response and prognosis. null France Bourgogne Franche-Comté Individuals Patients population Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Patients with breast cancer receiving neoadjuvant chemotherapy; - patient's written consent. Biological data Paraclinical data (non-biological) : Imaging Health event/morbidity Health event/mortality Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Converting or copying information into a structured record Observational Study Observational Study Cohort study 465 Unknown Restricted access Data may be used by academic teams. Data may not be used by industrial teams Data may be used by academic teams Access for biological portion of study carried out in INSERM Unit U866 (Prof. Eric Solary, Dr. Ghiringhelli) in Dijon and INSERM Unit 645 in Besançon Data may not be used by industrial teams Access on specific project only